Literature DB >> 27308458

Targeting the Warburg effect for leukemia therapy: Magnitude matters.

Ying-Hua Wang1, David T Scadden1.   

Abstract

Non-oxidative glucose metabolism represents a hallmark of cancer. It is now apparent that different cell states among normal stem or progenitor cells have distinct aerobic glycolysis (AG) dependencies. However, malignant cells are markedly more vulnerable to modifications of AG regardless of the differentiation state of their cell of origin.

Entities:  

Keywords:  aerobic glycolysis; hematopoiesis; leukemia; metabolism; progenitor cells; stem cells

Year:  2015        PMID： 27308458      PMCID： PMC4905293          DOI： 10.4161/23723556.2014.981988

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  [Origin of cancer cells].

Authors:  O WARBURG
Journal:  Oncologia       Date:  1956

2.  PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells.

Authors:  William J Israelsen; Talya L Dayton; Shawn M Davidson; Brian P Fiske; Aaron M Hosios; Gary Bellinger; Jie Li; Yimin Yu; Mika Sasaki; James W Horner; Laura N Burga; Jianxin Xie; Michael J Jurczak; Ronald A DePinho; Clary B Clish; Tyler Jacks; Richard G Kibbey; Gerburg M Wulf; Dolores Di Vizio; Gordon B Mills; Lewis C Cantley; Matthew G Vander Heiden
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

3.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Authors:  Andrei V Krivtsov; David Twomey; Zhaohui Feng; Matthew C Stubbs; Yingzi Wang; Joerg Faber; Jason E Levine; Jing Wang; William C Hahn; D Gary Gilliland; Todd R Golub; Scott A Armstrong
Journal:  Nature       Date:  2006-07-16       Impact factor: 49.962

4.  Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression.

Authors:  Anne Le; Charles R Cooper; Arvin M Gouw; Ramani Dinavahi; Anirban Maitra; Lorraine M Deck; Robert E Royer; David L Vander Jagt; Gregg L Semenza; Chi V Dang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-19       Impact factor: 11.205

5.  The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism.

Authors:  Cynthia V Clower; Deblina Chatterjee; Zhenxun Wang; Lewis C Cantley; Matthew G Vander Heiden; Adrian R Krainer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-19       Impact factor: 11.205

6.  Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization.

Authors:  N Takahashi; I Miura; K Saitoh; A B Miura
Journal:  Blood       Date:  1998-12-15       Impact factor: 22.113

7.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth.

Authors:  Heather R Christofk; Matthew G Vander Heiden; Marian H Harris; Arvind Ramanathan; Robert E Gerszten; Ru Wei; Mark D Fleming; Stuart L Schreiber; Lewis C Cantley
Journal:  Nature       Date:  2008-03-13       Impact factor: 49.962

8.  Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis.

Authors:  Ying-Hua Wang; William J Israelsen; Dongjun Lee; Vionnie W C Yu; Nathaniel T Jeanson; Clary B Clish; Lewis C Cantley; Matthew G Vander Heiden; David T Scadden
Journal:  Cell       Date:  2014-09-11       Impact factor: 41.582

9.  Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells.

Authors:  Han Xie; Jun-Ichi Hanai; Jian-Guo Ren; Lev Kats; Kerri Burgess; Parul Bhargava; Sabina Signoretti; Julia Billiard; Kevin J Duffy; Aaron Grant; Xiaoen Wang; Pawel K Lorkiewicz; Sabrina Schatzman; Michael Bousamra; Andrew N Lane; Richard M Higashi; Teresa W M Fan; Pier Paolo Pandolfi; Vikas P Sukhatme; Pankaj Seth
Journal:  Cell Metab       Date:  2014-04-10       Impact factor: 27.287

10.  Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis.

Authors:  Dimitrios Anastasiou; Yimin Yu; William J Israelsen; Jian-Kang Jiang; Matthew B Boxer; Bum Soo Hong; Wolfram Tempel; Svetoslav Dimov; Min Shen; Abhishek Jha; Hua Yang; Katherine R Mattaini; Christian M Metallo; Brian P Fiske; Kevin D Courtney; Scott Malstrom; Tahsin M Khan; Charles Kung; Amanda P Skoumbourdis; Henrike Veith; Noel Southall; Martin J Walsh; Kyle R Brimacombe; William Leister; Sophia Y Lunt; Zachary R Johnson; Katharine E Yen; Kaiko Kunii; Shawn M Davidson; Heather R Christofk; Christopher P Austin; James Inglese; Marian H Harris; John M Asara; Gregory Stephanopoulos; Francesco G Salituro; Shengfang Jin; Lenny Dang; Douglas S Auld; Hee-Won Park; Lewis C Cantley; Craig J Thomas; Matthew G Vander Heiden
Journal:  Nat Chem Biol       Date:  2012-10       Impact factor: 15.040
  10 in total
  4 in total

Review 1.  Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?

Authors:  Maximilian Stahl; Benjamin Y Lu; Tae Kon Kim; Amer M Zeidan
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

Review 2.  Insulin, insulin receptors, and cancer.

Authors:  R Vigneri; I D Goldfine; L Frittitta
Journal:  J Endocrinol Invest       Date:  2016-07-01       Impact factor: 4.256

3.  Use of real-time cellular analysis and Plackett-Burman design to develop the serum-free media for PC-3 prostate cancer cells.

Authors:  Ai Zhao; Fahai Chen; Chunhong Ning; Haiming Wu; Huanfang Song; Yanqing Wu; Rong Chen; Kaihua Zhou; Xiaoling Xu; Yinxiang Lu; Jimin Gao
Journal:  PLoS One       Date:  2017-09-25       Impact factor: 3.240

4.  Hexokinase II inhibition by 3-bromopyruvate sensitizes myeloid leukemic cells K-562 to anti-leukemic drug, daunorubicin.

Authors:  Yogesh Rai; Priyanshu Yadav; Neeraj Kumari; Namita Kalra; Anant Narayan Bhatt
Journal:  Biosci Rep       Date:  2019-09-24       Impact factor: 3.840
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.